MarketCap
Facebook
X
Telegram
Anika Therapeutics Financial Ratios 2025-2008 | ANIK
Brief overview of Anika Therapeutics's multiples and efficiency
Current figures are compared with the company's own five-year history for 2016–2021.
The latest available valuation ratios are P/E 110.78x (median 29.25x), EV/EBITDA 91.9x (median 38.71x), P/S 1.9x (median 3.09x). The combined ratio level is close to the company's five-year norm at a -3.3% deviation. No clear premium or discount is visible.
At the current P/E, inverse earnings yield is 0.9%, a useful bridge between price and business earnings.
End-period return metrics are ROE -7.6%, ROA -5.7%, ROCE -7.7%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
PEG is 0.15x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.
The time from paying for inputs to receiving cash fell from 251.2 days to 191.7 days. Cash turnover improved.
Valuation takeaway
Anika Therapeutics's market valuation is near its own historical norm, while quality ratios provide no extreme signal.
Annual Financial Ratios Anika Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-19.7 | -3.9 | -4.5 | -27.3 | 110.8 | -21.9 | 22.3 | 29.3 | 31.2 | 22.4 | 18.3 | 15.0 | 22.9 | 12.0 | 14.0 | 18.0 | 16.1 | - |
P/S |
1.9 | 1.8 | 3.1 | 3.6 | 3.1 | 4.0 | 5.3 | 5.2 | 8.8 | 7.1 | 6.0 | 5.4 | 6.3 | 2.0 | 1.8 | - | - | - |
EPS |
-0.8 | -3.8 | -5.6 | -1.0 | 0.3 | -1.7 | 1.9 | 1.3 | 2.2 | 2.2 | 2.1 | 2.6 | 1.5 | 0.9 | 0.7 | 0.3 | 0.3 | - |
EV (Enterprise Value) |
156 M | 164 M | 304 M | 319 M | 364 M | 431 M | 491 M | 474 M | 880 M | 643 M | 476 M | 491 M | 429 M | 130 M | 121 M | 49.3 M | 34.8 M | -43.2 M |
EBITDA per Share |
-0.4 | 0.12 | 0.5 | 0.71 | 0.63 | -1.56 | 2.85 | 1.92 | 3.43 | 3.7 | 3.48 | 4.51 | 2.63 | 2.02 | 1.38 | 0.86 | 0.6 | - |
EV/EBITDA |
-27.5 | 91.9 | 41.8 | 30.8 | 38.7 | -429.8 | 11.2 | 16.6 | 17.2 | 11.5 | 8.7 | 7.2 | 11.0 | 4.0 | 5.2 | 4.5 | 5.1 | - |
PEG |
0.15 | 0.05 | 0.09 | 0.49 | -1.86 | 0.73 | 0.46 | -0.72 | -17.34 | 2.89 | -0.87 | 0.19 | 0.36 | 0.33 | 0.15 | - | - | - |
P/B |
1.1 | 1.1 | 1.4 | 1.2 | 1.3 | 1.4 | 2.1 | 2.1 | 3.8 | 3.3 | 2.7 | 3.2 | 3.5 | 1.3 | 1.3 | 0.6 | - | - |
P/CF |
19.1 | 40.6 | -208.5 | 92.0 | 54.5 | 40.3 | 17.7 | 18.1 | 31.2 | 74.6 | 18.8 | 15.0 | 19.1 | 15.6 | 13.6 | 9.9 | 19.1 | - |
ROE % |
-7.58 | -36.62 | -38.95 | -5.20 | 1.44 | -8.80 | 9.43 | 7.10 | 12.07 | 14.61 | 14.59 | 21.52 | 15.17 | 10.79 | 8.93 | 5.07 | 4.49 | - |
ROA % |
-5.72 | -27.81 | -30.55 | -4.26 | 1.19 | -6.56 | 8.22 | 6.71 | 11.26 | 13.55 | 13.05 | 19.75 | 13.19 | 8.28 | 6.37 | 3.35 | - | - |
ROCE % |
-7.70 | -3.31 | 0.40 | 1.29 | 0.91 | -10.40 | 10.89 | 8.12 | 16.97 | 21.87 | 22.03 | 32.68 | 22.02 | 17.44 | 11.81 | 8.85 | 6.80 | - |
Current Ratio |
- | - | - | - | - | - | 14.4 | 18.3 | 15.8 | 19.4 | 10.2 | 23.3 | 10.2 | 5.4 | 4.4 | - | - | - |
DSO |
76.5 | 76.0 | 92.1 | 103.4 | 66.6 | 66.0 | 73.5 | 71.8 | 76.7 | 97.4 | 85.0 | 59.3 | 91.1 | 109.8 | 97.5 | - | - | - |
DIO |
158.6 | 200.5 | 306.2 | 340.6 | 231.4 | 202.6 | 279.3 | 293.3 | 293.9 | 242.8 | 259.0 | 216.4 | 176.3 | 104.3 | 99.5 | - | - | - |
DPO |
43.4 | 49.1 | 72.8 | 75.1 | 46.8 | 38.1 | 48.7 | 36.7 | 90.0 | 35.0 | 143.9 | 20.9 | 44.8 | 29.5 | 58.6 | - | - | - |
Operating Cycle |
235.1 | 276.5 | 398.3 | 443.9 | 298.0 | 268.6 | 352.8 | 365.1 | 370.6 | 340.2 | 344.0 | 275.6 | 267.4 | 214.1 | 197.0 | - | - | - |
Cash Conversion Cycle |
191.7 | 227.4 | 325.5 | 368.8 | 251.2 | 230.6 | 304.1 | 328.4 | 280.6 | 305.3 | 200.0 | 254.7 | 222.6 | 184.6 | 138.4 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Anika Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.25 | -0.37 | -0.16 | -0.28 | -0.34 | - | -2.03 | -0.01 | -0.31 | - | -0.45 | -0.19 | -0.71 | - | -0.29 | -0.2 | -0.2 | - | 0.04 | 0.45 | 0.2 | -1.1 | -0.45 | -0.54 | 0.41 | 0.28 | 0.65 | 0.68 | 0.32 | 0.54 | 0.53 | 0.69 | -0.46 | 0.55 | 0.47 | 0.78 | 0.38 | 0.56 | 0.61 | 0.59 | 0.46 | 0.74 | 0.56 | 0.52 | 0.24 | 0.53 | 0.42 | 0.63 | 1.04 | 0.47 | 0.36 | 0.44 | 0.23 | 0.33 | 0.12 | 0.28 | 0.15 | 0.22 | 0.23 | 0.18 | 0.03 |
EBITDA per Share |
0.44 | -0.3 | 0.06 | -0.11 | -0.2 | - | 0.08 | -0.04 | -0.05 | - | -0.39 | -0.11 | -0.75 | - | -0.06 | -0.1 | -0.13 | - | 0.42 | 0.78 | 0.2 | - | -0.24 | -0.22 | 0.69 | - | 1.17 | 1.07 | 0.49 | - | 0.91 | 0.97 | -0.43 | - | 0.93 | 1.35 | 0.62 | - | 1.13 | 1.05 | 0.78 | - | 1.06 | 0.95 | 0.43 | - | 0.94 | 1.2 | 1.73 | - | 0.83 | 0.86 | 0.46 | - | 0.46 | 0.63 | 0.31 | - | 0.61 | 0.44 | 0.12 |
ROE % |
-5.64 | -11.33 | -24.19 | -22.65 | -22.12 | -18.84 | -21.27 | -5.64 | -9.32 | -7.16 | -8.63 | -7.19 | -7.21 | -3.49 | -3.29 | 0.45 | 2.47 | 3.50 | -2.25 | -4.80 | -9.91 | -8.80 | -1.65 | 3.89 | 9.99 | 9.43 | 10.95 | 10.64 | 11.20 | 7.10 | 7.24 | 6.97 | 7.45 | 12.07 | 12.64 | 14.05 | 13.60 | 14.61 | 16.22 | 16.17 | 16.02 | 14.59 | 13.74 | 13.23 | 14.74 | 21.52 | 22.03 | 22.22 | 21.35 | 15.17 | 14.36 | 12.22 | 11.30 | 10.79 | 9.74 | 11.37 | 10.35 | 8.93 | 3.14 | 2.41 | 0.34 |
ROA % |
-4.36 | -8.72 | -18.83 | -17.63 | -17.23 | -14.67 | -15.51 | -5.63 | -6.80 | -5.09 | -5.09 | -5.94 | -4.95 | -1.90 | -0.10 | 1.10 | 1.88 | 2.74 | -1.54 | -3.45 | -7.36 | -6.56 | -1.05 | 3.48 | 8.44 | 8.22 | 9.76 | 9.71 | 10.47 | 6.71 | 6.80 | 6.51 | 6.92 | 11.26 | 11.77 | 13.06 | 12.62 | 13.55 | 14.87 | 14.69 | 14.43 | 13.05 | 12.42 | 12.04 | 13.52 | 19.78 | 19.99 | 19.98 | 18.97 | 13.19 | 12.06 | 10.04 | 8.90 | 8.28 | 7.30 | 8.39 | 7.48 | 6.37 | 2.24 | 1.72 | 0.24 |
ROCE % |
-6.98 | -12.02 | -7.96 | -6.62 | -4.99 | -2.11 | -4.94 | -6.22 | -9.89 | -8.68 | -10.72 | -9.06 | -8.98 | -4.46 | -4.01 | 1.22 | 2.86 | 4.10 | 1.19 | -2.76 | -3.35 | -3.81 | 0.37 | 7.41 | 12.82 | 10.21 | 13.46 | 13.55 | 6.45 | 4.55 | 8.44 | 11.92 | 10.69 | 13.66 | 19.81 | 21.96 | 20.04 | 17.00 | 23.23 | 22.98 | 19.54 | 14.73 | 20.51 | 22.82 | 30.33 | 27.71 | 33.44 | 34.59 | 29.75 | 16.35 | 18.85 | 18.76 | 14.64 | 10.95 | 16.03 | 17.41 | 12.36 | 9.55 | 5.08 | 3.88 | 0.59 |
DSO |
76.7 | 73.9 | 75.7 | 74.3 | 79.5 | - | 95.9 | 97.8 | 107.0 | - | 40.4 | 69.4 | 36.9 | - | - | - | 37.1 | - | 71.3 | 66.9 | 67.3 | 67.3 | 69.4 | 71.7 | 60.8 | 70.7 | 70.9 | 69.2 | 80.9 | 70.3 | 70.8 | 62.1 | 95.7 | 74.0 | 80.0 | 65.0 | 100.3 | 87.7 | 97.7 | 94.7 | 100.8 | 64.0 | 83.4 | 86.3 | 114.1 | 67.3 | 71.0 | 59.6 | 48.1 | 80.5 | 96.3 | 82.1 | 120.3 | 86.6 | 132.6 | 99.8 | 123.2 | 85.6 | 85.6 | 97.8 | - |
DIO |
206.3 | 168.2 | 123.8 | 126.0 | 179.3 | - | 409.4 | 449.7 | 435.0 | - | 117.7 | 249.8 | 245.3 | - | 97.2 | 108.6 | 218.3 | - | 215.2 | 225.3 | 304.6 | - | 293.8 | 249.0 | 219.1 | 232.1 | 337.3 | 293.6 | 270.2 | 277.6 | 234.7 | 238.4 | 252.0 | 230.7 | 321.7 | 318.4 | 285.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
50.5 | 47.6 | 35.4 | 33.1 | 43.3 | - | 75.5 | 89.2 | 90.3 | - | 21.9 | 50.3 | 54.5 | - | 21.8 | 23.0 | 46.2 | - | 44.3 | 44.2 | 60.5 | - | 57.1 | 48.4 | 41.2 | 40.4 | 58.8 | 51.1 | 43.5 | 41.0 | 34.6 | 35.2 | 57.5 | 70.6 | 98.5 | 97.5 | 67.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 199.5 | 200.3 | 258.8 | - | 505.3 | 547.5 | 542.0 | - | - | 319.1 | 282.2 | - | 97.2 | 108.6 | 255.4 | - | 286.5 | 292.2 | 372.0 | 67.3 | 363.2 | 320.7 | 279.9 | 302.8 | 408.2 | 362.8 | 351.1 | 347.9 | 305.4 | 300.5 | 347.7 | 304.7 | 401.7 | 383.4 | 385.5 | 87.7 | 97.7 | 94.7 | 100.8 | 64.0 | 83.4 | 86.3 | 114.1 | 67.3 | 71.0 | 59.6 | 48.1 | 80.5 | 96.3 | 82.1 | 120.3 | 86.6 | 132.6 | 99.8 | 123.2 | 85.6 | 85.6 | 97.8 | - |
Cash Conversion Cycle |
- | - | 164.1 | 167.2 | 215.5 | - | 429.8 | 458.2 | 451.7 | - | - | 268.9 | 227.6 | - | 75.4 | 85.7 | 209.2 | - | 242.1 | 248.0 | 311.5 | 67.3 | 306.1 | 272.2 | 238.8 | 262.4 | 349.4 | 311.7 | 307.6 | 307.0 | 270.8 | 265.3 | 290.2 | 234.0 | 303.2 | 285.9 | 317.6 | 87.7 | 97.7 | 94.7 | 100.8 | 64.0 | 83.4 | 86.3 | 114.1 | 67.3 | 71.0 | 59.6 | 48.1 | 80.5 | 96.3 | 82.1 | 120.3 | 86.6 | 132.6 | 99.8 | 123.2 | 85.6 | 85.6 | 97.8 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Anika Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
